We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for LexinFintech (LX) in Q2 Earnings?
Read MoreHide Full Article
LexinFintech Holdings Ltd. (LX - Free Report) is slated to announce second-quarter 2019 results on Aug 30, before the market opens.
In the first quarter of 2019, the company’s earnings surpassed the Zacks Consensus Estimate. Results benefited from an increase in total operating revenues, partly offset by higher expenses.
Factors to Influence Q2 Results
Given continued growth in LexinFintech’s business, its loan origination volume in the to-be-reported quarter is likely to increase.
Therefore, with higher loan origination volume, the company’s loan facilitation and servicing fees are likely to improve, thereby aiding total financial services income. However, a slowdown in the China economy may have a slight adverse impact on top-line growth.
On the cost front, the company’s operating expenses have remained elevated over the past few quarters. In fact, given the continued rise in share-based compensation costs, overall expenses are likely to increase this time as well.
LexinFintech Holdings Ltd. Sponsored ADR Price and Consensus
Currently, the company carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the finance space are T. Rowe Price Group, Inc. (TROW - Free Report) , Victory Capital Holdings, Inc. (VCTR - Free Report) and AllianceBernstein Holding L.P. (AB - Free Report) .
Over the past 60 days, T. Rowe Price’s Zacks Consensus Estimate for current-year earnings has been revised 3.6% upward. Its share price has increased 16.7% year to date. The stock currently sports a Zacks Rank #1 (Strong Buy).
Victory Capital has witnessed an upward earnings estimate revision of 5% for 2019, over the past 60 days. So far this year, the company’s share price has increased 48.6%. The stock sports a Zacks Rank of 1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
AllianceBernstein has witnessed an upward earnings estimate revision of 2.1% for 2019 over the past 60 days. Its share price has risen 3.9% so far this year. The stock currently carries a Zacks Rank #2 (Buy).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
What's in the Cards for LexinFintech (LX) in Q2 Earnings?
LexinFintech Holdings Ltd. (LX - Free Report) is slated to announce second-quarter 2019 results on Aug 30, before the market opens.
In the first quarter of 2019, the company’s earnings surpassed the Zacks Consensus Estimate. Results benefited from an increase in total operating revenues, partly offset by higher expenses.
Factors to Influence Q2 Results
Given continued growth in LexinFintech’s business, its loan origination volume in the to-be-reported quarter is likely to increase.
Therefore, with higher loan origination volume, the company’s loan facilitation and servicing fees are likely to improve, thereby aiding total financial services income. However, a slowdown in the China economy may have a slight adverse impact on top-line growth.
On the cost front, the company’s operating expenses have remained elevated over the past few quarters. In fact, given the continued rise in share-based compensation costs, overall expenses are likely to increase this time as well.
LexinFintech Holdings Ltd. Sponsored ADR Price and Consensus
LexinFintech Holdings Ltd. Sponsored ADR price-consensus-chart | LexinFintech Holdings Ltd. Sponsored ADR Quote
Currently, the company carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the finance space are T. Rowe Price Group, Inc. (TROW - Free Report) , Victory Capital Holdings, Inc. (VCTR - Free Report) and AllianceBernstein Holding L.P. (AB - Free Report) .
Over the past 60 days, T. Rowe Price’s Zacks Consensus Estimate for current-year earnings has been revised 3.6% upward. Its share price has increased 16.7% year to date. The stock currently sports a Zacks Rank #1 (Strong Buy).
Victory Capital has witnessed an upward earnings estimate revision of 5% for 2019, over the past 60 days. So far this year, the company’s share price has increased 48.6%. The stock sports a Zacks Rank of 1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
AllianceBernstein has witnessed an upward earnings estimate revision of 2.1% for 2019 over the past 60 days. Its share price has risen 3.9% so far this year. The stock currently carries a Zacks Rank #2 (Buy).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>